Abstract：
Targeted alpha therapy is an emerging alternative for palliative therapy of a wide range of tumor types. Data from preclinicaland clinical research demonstrates a high potential for the selective killing of tumor cells and minimal toxicity to surroundinghealthy tissues. This article summarizes the developmental stages of alpha-targeted therapy from benchtop to commercialization.It discusses fundamental properties, production pathways, microdosimetry, and possible targeting vectors. Proper coverage hasalso been given to comparing it with other standard treatment procedures while exploring clinical applications of alpha emitters.In the end, like other therapies, the challenges it faces and its future impact on personalized medicine are also illustrated.
摘要：
靶向α治疗是广泛肿瘤类型的姑息治疗的新兴替代方案。来自临床前和临床研究的数据表明，选择性杀死肿瘤细胞的潜力很大，对周围隐形组织的毒性最小。本文总结了α靶向治疗从基准到商业化的发展阶段。它讨论了基本属性，生产途径，微剂量测定，和可能的靶向载体。在探索α发射体的临床应用时，还将其与其他标准治疗程序进行了比较。最后,像其他疗法一样，还说明了它面临的挑战及其对个性化医疗的未来影响。
